2010 surveillance of bacterial resistance in Xiangya hospital
Wenen Liu
Abstract
Wenen Liu
Abstract
【Objective】 To investigate the distribution and antibiotic resistance of clinical isolates collected from Xiangya Hospital of Central South University from January 1 to December 31,2010.【Methods】 Identification of isolates and antimicrobial susceptibility test was carried out by Vitek 2 system and data were analyzed by WHONET 5.4 software according to CLSI 2010 standards.【Results】 A total of 5 011 isolates were collected,in which gram negative bacteria,gram positive bacteria and fungus accounted for 53.5%(2 684/5 011),28.3%(1 417/5 011) and 18.2%(910/5 011),respectively.Methicillin resistant Staphylococcus aureus(MRSA) and coagulase-negative Staphylococcus(MRCNS) accounted for 60.4%(142/235) and 55.6%(262/409),respectively.No vancomycin,linezolid or teicoplanin resistant Staphylococcus was found,but 3 vancomycin resistant Enterococcus faecium were isolated.Extended Spectrum Beta-Lactamases(ESBLs)-producing strains accounted for 77.6%(470/606) of Escherichia coli and 58.4%(211/361) of Klebsiella pneumoniae.Enterobacteriaceae remained highly sensitive to cefoperazone/ sulbactam and carbapenem,and the resistance rates were 0.9%~15.8% and 0.5%~10.1%,respectively.Resistance rates of pseudomonas aeruginosa to imipenem and meropenem were 15.8% and 17.3%,respectively.Resistance rates of acinetobacter baumannii to imipenem and meropenem were 49.4% and 29.7%.A few pan-drug resistant strains of P.aeruginosa and acinetobacter spp.were isolated.【Conclusions】 Drug resistance of clinical isolates is severe in this hospital.Therefore,we should strengthen the surveillance of antimicrobial resistance and pay more attention to the changes of antimicrobial resistance in order to provide laboratory basis for rational selection of antimicrobial agents.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
【Objective】 To investigate the distribution and antibiotic resistance of clinical isolates collected from Xiangya Hospital of Central South University from January 1 to December 31,2010.【Methods】 Identification of isolates and antimicrobial susceptibility test was carried out by Vitek 2 system and data were analyzed by WHONET 5.4 software according to CLSI 2010 standards.【Results】 A total of 5 011 isolates were collected,in which gram negative bacteria,gram positive bacteria and fungus accounted for 53.5%(2 684/5 011),28.3%(1 417/5 011) and 18.2%(910/5 011),respectively.Methicillin resistant Staphylococcus aureus(MRSA) and coagulase-negative Staphylococcus(MRCNS) accounted for 60.4%(142/235) and 55.6%(262/409),respectively.No vancomycin,linezolid or teicoplanin resistant Staphylococcus was found,but 3 vancomycin resistant Enterococcus faecium were isolated.Extended Spectrum Beta-Lactamases(ESBLs)-producing strains accounted for 77.6%(470/606) of Escherichia coli and 58.4%(211/361) of Klebsiella pneumoniae.Enterobacteriaceae remained highly sensitive to cefoperazone/ sulbactam and carbapenem,and the resistance rates were 0.9%~15.8% and 0.5%~10.1%,respectively.Resistance rates of pseudomonas aeruginosa to imipenem and meropenem were 15.8% and 17.3%,respectively.Resistance rates of acinetobacter baumannii to imipenem and meropenem were 49.4% and 29.7%.A few pan-drug resistant strains of P.aeruginosa and acinetobacter spp.were isolated.【Conclusions】 Drug resistance of clinical isolates is severe in this hospital.Therefore,we should strengthen the surveillance of antimicrobial resistance and pay more attention to the changes of antimicrobial resistance in order to provide laboratory basis for rational selection of antimicrobial agents.
Key concepts: Microbiology, Meropenem, Imipenem, Acinetobacter baumannii, Teicoplanin, Linezolid, Sulbactam, Vancomycin